Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI Worldwide, MilanCPhI Worldwide, Milan
Not Confirmed
Not Confirmed
08-10 October, 2024
Not Confirmed
Not Confirmed
26-27 September, 2024
Oligo Chemistry & Ther...Oligo Chemistry & Therapeutics 2024
Not Confirmed
Not Confirmed
27 September, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Not Confirmed
08-10 October, 2024
Industry Trade Show
Not Confirmed
26-27 September, 2024
Oligo Chemistry & Ther...Oligo Chemistry & Therapeutics 2024
Webinar
Not Confirmed
27 September, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/ice-is-pioneering-sustainability-innovation-in-bile-acid-research-for-neurodegenerative-diseases
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/2024-us-elections-harris-trump-differ-on-abortion-rights-aca-public-health-spends-agree-on-need-to-cut-drug-prices
Details:
Solifenacin Succinate is a muscarinic receptor antagonist and tamsulosin is an alpha-1A and alpha-1B adrenergic receptor antagonist used in combination to treat benign prostatic hyperplasia.
Lead Product(s): Solifenacin Succinate,Tamsulosin
Therapeutic Area: Urology Brand Name: Vesomni-Generic
Study Phase: ApprovedProduct Type: Small molecule
Recipient: Adalvo
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Lead Product(s) : Solifenacin Succinate,Tamsulosin
Therapeutic Area : Urology
Highest Development Status : Approved
Recipient : Adalvo
Deal Size : Not Applicable
Deal Type : Not Applicable
Adalvo and Adamed Pharma Team up to Launch Solifenacin + Tamsulosin in Europe
Details : Solifenacin Succinate is a muscarinic receptor antagonist and tamsulosin is an alpha-1A and alpha-1B adrenergic receptor antagonist used in combination to treat benign prostatic hyperplasia.
Brand Name : Vesomni-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 23, 2023
Regulatory Info : Generic
Registration Country : Poland
Dosage Form :
Brand Name :
Dosage Strength :
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Poland
Regulatory Info : Generic
Registration Country : Poland
Dosage Form : TABLET
Brand Name :
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Poland
Regulatory Info : Generic
Registration Country : Poland
Dosage Form : TABLET
Brand Name :
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Poland
Regulatory Info : Generic
Registration Country : Poland
Amlodipine Besylate; Candesartan Cilexetil
Dosage Form : CAPSULE
Brand Name :
Dosage Strength : 8MG; 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Poland
Regulatory Info : Generic
Registration Country : Poland
Amlodipine Besylate; Candesartan Cilexetil
Dosage Form : CAPSULE
Brand Name :
Dosage Strength : 16MG; 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Poland
Regulatory Info : Generic
Registration Country : Poland
Amlodipine Besylate; Candesartan Cilexetil
Dosage Form : CAPSULE
Brand Name :
Dosage Strength : 8MG; 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Poland
Regulatory Info : Generic
Registration Country : Poland
Amlodipine Besylate; Candesartan Cilexetil
Dosage Form : CAPSULE
Brand Name :
Dosage Strength : 16MG; 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Poland
Regulatory Info : Generic
Registration Country : Poland
Amlodipine Besylate; Perindopril
Dosage Form : CAPSULE
Brand Name :
Dosage Strength : 4MG; 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Poland
Regulatory Info : Generic
Registration Country : Poland
Amlodipine Besylate; Perindopril
Dosage Form : CAPSULE
Brand Name :
Dosage Strength : 8MG; 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Poland
Regulatory Info : Generic
Registration Country : Poland
Amlodipine Besylate; Perindopril
Dosage Form : CAPSULE
Brand Name :
Dosage Strength : 4MG; 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Poland
Regulatory Info : Generic
Registration Country : Poland
Dosage Form :
Dosage Strength :
Packaging :
Brand Name :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Poland
Regulatory Info : Generic
Registration Country : Poland
Dosage Form : TABLET
Dosage Strength : 5MG
Packaging :
Brand Name :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Poland
Regulatory Info : Generic
Registration Country : Poland
Dosage Form : TABLET
Dosage Strength : 10MG
Packaging :
Brand Name :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Poland
Regulatory Info : Generic
Registration Country : Poland
Amlodipine Besylate; Candesartan Cilexetil
Dosage Form : CAPSULE
Dosage Strength : 8MG; 5MG
Packaging :
Brand Name :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Poland
Regulatory Info : Generic
Registration Country : Poland
Amlodipine Besylate; Candesartan Cilexetil
Dosage Form : CAPSULE
Dosage Strength : 8MG; 10MG
Packaging :
Brand Name :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Poland
Regulatory Info : Generic
Registration Country : Poland
Amlodipine Besylate; Candesartan Cilexetil
Dosage Form : CAPSULE
Dosage Strength : 16MG; 5MG
Packaging :
Brand Name :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Poland
Regulatory Info : Generic
Registration Country : Poland
Amlodipine Besylate; Candesartan Cilexetil
Dosage Form : CAPSULE
Dosage Strength : 16MG; 10MG
Packaging :
Brand Name :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Poland
Regulatory Info : Generic
Registration Country : Poland
Amlodipine Besylate; Perindopril
Dosage Form : CAPSULE
Dosage Strength : 4MG; 5MG
Packaging :
Brand Name :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Poland
Regulatory Info : Generic
Registration Country : Poland
Amlodipine Besylate; Perindopril
Dosage Form : CAPSULE
Dosage Strength : 4MG; 10MG
Packaging :
Brand Name :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Poland
Regulatory Info : Generic
Registration Country : Poland
Amlodipine Besylate; Perindopril
Dosage Form : CAPSULE
Dosage Strength : 8MG; 5MG
Packaging :
Brand Name :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Poland
Inspections and registrations
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?